Literature DB >> 18043452

Progress in measles and rubella elimination in Iran.

Abdoulreza Esteghamati1, Mohammad Mehdi Gouya, Seyed Mohsen Zahraei, Mohammad Nasr Dadras, Armin Rashidi, Frank Mahoney.   

Abstract

BACKGROUND: Measles is a leading cause of death worldwide because of vaccine preventable diseases. Prevention and control of measles and rubella is a high priority for the Islamic Republic of Iran. In 2002, the Ministry of Health and Medical Education in Iran developed a comprehensive strategy to eliminate measles and rubella. This strategy included recommendations for a mass immunization campaign for all persons between the ages of 5-25 years with measles-rubella (MR) vaccine. This report reviews the results of this campaign and progress in the elimination of measles and rubella in Iran.
METHODS: Measles vaccination coverage, supplemental immunization activities, surveillance data, and results from a nationwide serosurvey were reviewed.
RESULTS: Between 1980 and 2005, vaccination coverage ranged from 38%-99% with sustained high coverage (> or =94-99%) for the past decade. Despite high coverage with the first dose of measles vaccine (MCV1) and the introduction of a second dose of measles in 1984, case counts remained high between 1980 and 2005 with a median case count of 4414. In December 2003, a nationwide immunization campaign was conducted targeting 33,579,082 people between the ages of 5 and 25 years with a combined measles and rubella vaccine; 98% of the target population was vaccinated. A postcampaign serosurvey conducted in 2004 revealed >97.4% of the population aged between 5 and 40 years had immunity to measles and rubella. Case-based surveillance for measles identified 3 children with laboratory confirmed disease in 2004, 35 in 2005, and 42 children in 2006. Most confirmed disease occurred in immigrant communities or communities with migrant populations from neighboring counties with ongoing measles outbreaks. Surveillance for rubella was established after the campaign and identified 37 patients with confirmed disease in the follow-up period.
CONCLUSIONS: Implementation of a comprehensive strategy for measles elimination in Iran has remarkably reduced the incidence of measles and rubella to <1 case per 1,000,000. Sporadic transmission continues to occur, particularly in areas with immigrant and nomadic populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18043452     DOI: 10.1097/INF.0b013e3181462090

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  21 in total

1.  Reiteration of the elimination status of measles in the southeast of Iran, 2015.

Authors:  Shahrokh Izadi; Masoome Arabsalmani; Mahdi Mohammadi; Seyed Mehdi Tabatabaei; Ali-Akbar Haghdoost
Journal:  Hum Vaccin Immunother       Date:  2018-09-05       Impact factor: 3.452

2.  National Immunization Program in Iran: whys and why nots.

Authors:  Maziar Moradi-Lakeh; Abdoulreza Esteghamati
Journal:  Hum Vaccin Immunother       Date:  2013-01       Impact factor: 3.452

3.  Seroprevalence of antibodies to measles and rubella eight months after a vaccination campaign in the southeast of Iran.

Authors:  Shahrokh Izadi; Seyed Mohsen Zahraei; Talat Mokhtari-Azad
Journal:  Hum Vaccin Immunother       Date:  2018-02-26       Impact factor: 3.452

4.  A Nationwide Study on the Seroprevalence of Measles, Mumps, and Rubella in Iranian Children and Adolescents.

Authors:  Zary Nokhodian; Behrooz Ataei; Mohammad Mehdi Gouya; Shervin Ghaffari Hoseini; Majid Yaran; Marjan Mansourian; Mohammad Esmaeil Motlagh; Ramin Heshmat; Seyed Mohsen Zahraei; Roya Kelishadi
Journal:  Iran J Public Health       Date:  2022-02       Impact factor: 1.479

5.  Factors affecting the seroconversion rate of 12-month-old babies after the first injection of measles vaccine in the southeast of Iran.

Authors:  Seyed Mohsen Zahraei; Shahrokh Izadi; Talat Mokhtari-Azad
Journal:  Hum Vaccin Immunother       Date:  2016-07-26       Impact factor: 3.452

6.  Sero-epidemiological evaluation of rubella immunity among pre-marriage women in Iran.

Authors:  Seyed Mohsen Zahraei; Talat Mokhtari-Azad; Azam Sabouri; Salman Khazaei; Manoochehr Karami
Journal:  Hum Vaccin Immunother       Date:  2019-07-11       Impact factor: 3.452

7.  Inequity in Timeliness of MMR Vaccination in Children Living in the Suburbs of Iranian Cities.

Authors:  Rahmatollah Jadidi; Abolfazl Mohammadbeigi; Narges Mohammadsalehi; Hossein Ansari; Ebrahim Ghaderi
Journal:  Int J Biomed Sci       Date:  2015-06

8.  Molecular Epidemiology of Measles Virus before and after the 2003 Mass Vaccination Campaign for Measles/Rubella in Iran.

Authors:  M Naseri; V Salimi; T Mokhtari-Azad; A Esteghamati; Mm Gooya; Sa Nadji; Z Noroozbabaei; Sm Marashi; Z Saadatmand; F Rezaei; R Hamkar; H Triki
Journal:  Iran J Public Health       Date:  2011-03-31       Impact factor: 1.429

9.  Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign.

Authors:  Behnam Honarvar; Mohsen Moghadami; Afagh Moattari; Amir Emami; Neda Odoomi; Kamran Bagheri Lankarani
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Mass measles vaccination.

Authors:  Gholam Ali Ghorbani
Journal:  Iran J Med Sci       Date:  2012-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.